Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provides written informed consent to participate in the study
At least 18 but no more than 65 years old
Documented clinical diagnosis of a relapsing form of multiple sclerosis or confirmed clinically isolated syndrome (CIS)
Initiating Betaseron therapy, or resuming Betaseron after not having used it for at least three months
Willing and able to provide a valid e-mail address which will be in use for the duration of the study
Willing and able to complete study questionnaires via the Internet
Has reliable Internet access for the duration of the study
Completes the baseline patient questionnaire
You may not be if
Kurtzke Expanded Disability Status Scale (EDSS) score greater than 6.0
Cognitive dysfunction that, in the Investigator's judgment, raises doubts about the study participant's ability to provide informed consent or accurately complete the monthly patient questionnaire
Any use of Betaseron within the three months prior to study entry
Inability to read, write, or speak the English language
Illness or disease other than multiple sclerosis that the Investigator believes is likely to cause the patient's death or incapacity within twelve months
Any severe, uncontrolled illness or condition that the Investigator believes could dominate the patient's quality of life
Coexistent autoimmune disease such as rheumatoid arthritis, lupus, or psoriasis that is likely to be exacerbated by treatment with Interferon
Current use of any immunosuppressive medication
Previous participation in a multiple sclerosis (MS) clinical trial within the three months prior to study entry
Previous use of monoclonal antibodies treating MS within the three months prior to study entry
Current use of any secondary treatment for multiple sclerosis other than the episodic use of steroids during relapses or exacerbations
